BNC 105

Drug Profile

BNC 105

Alternative Names: BNC 105P; BNC-105

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iliad Chemicals
  • Developer Bionomics
  • Class Anisoles; Antineoplastics; Benzofurans; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Mesothelioma; Renal cell carcinoma
  • Phase I/II Ovarian cancer
  • Preclinical Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 01 Dec 2016 Bionomics completes a phase I/II trial in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Singapore, Australia (IV) (NCT01034631)
  • 28 Aug 2015 BNC 105 is still in phase II development for mesothelioma, renal cell carcinoma and phase I/II development for ovarian cancer in Australia, New Zealand and USA
  • 15 Jun 2015 Preclinical trials in Colorectal cancer in Australia (IV) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top